Format

Send to

Choose Destination
Arch Pharm Res. 2016 Dec;39(12):1609-1620. doi: 10.1007/s12272-016-0821-x. Epub 2016 Aug 29.

The role of Pin1 in the development and treatment of cancer.

Author information

1
New Drug Development Center, DGMIF, 80 Cheombok-ro Dong-gu, Daegu, 701-310, Korea. shmin03@dgmif.re.kr.
2
Division of Translational Therapeutics, Department of Medicine and Cancer Research Institute, Center for Life Science, Beth Israel Deaconess Medical Center, Harvard Medical School, Room 0408, 330 Brookline Avenue, Boston, MA, 02215, USA. klu@bidmc.harvard.edu.
3
Institute for Translational Medicine, Fujian Medical University, Fuzhou, 350108, China. klu@bidmc.harvard.edu.

Abstract

Protein phosphorylation and post-phosphorylation events regulate many cellular signaling pathways. Peptidyl-prolyl isomerase (Pin1) is the only peptidyl-prolyl cis/trans isomerase that interacts with numerous oncogenic or tumor suppressive phosphorylated proteins, causes conformational changes in target proteins, and eventually regulates the activities of such proteins. These alterations in activity play a pivotal role in tumorigenesis. Since Pin1 is overexpressed and/or activated in various types of cancers, and the dysregulation of proline-directed phosphorylation contributes to tumorigenesis, Pin1 represents an attractive target for cancer therapy. This review will describe the role of Pin1 in cancer and the current status of Pin1 inhibitor development.

KEYWORDS:

Cancer-driving pathways; Pin1; Pin1 inhibitor; Proline-directed phosphorylation; Prolyl isomerase; Tumorigenesis

PMID:
27572155
DOI:
10.1007/s12272-016-0821-x
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Springer
Loading ...
Support Center